Taglich Brothers Analyst Report on ALRT in PowerPoint

ALR Technologies (ALRT)

Leading research firm Taglich Brothers has initiated coverage on ALR Technologies, Inc. (OTCBB: ALRT) with a 12-month price target set at 50 cents.  Shares are trading today at 8 cents.  ALR maintains a relatively low profile in the investment community, but Taglich apparently sees some substantial upside based on their extensive analyst report.

The chart has been holding a baseline for years at this price point, which we will update in a video stock chart this week.  Those closely following ALRT have viewed their investor presentation which showcases the corporate strategies and provides examples of potential market penetration, which could approach $1.4 billion annually.  The presentation from a recent investor conference call can be viewed in video format at

There could be numerous catalysts to drive the company quickly back to the 25 cent price point from November 2011 when ALR announced receiving FDA 510(k) clearance for its Health-e-Connect (HeC) system as a technology for remote diabetes management.   The big news that has investors’ eyes open and ears to the ground is for CMS (Centers for Medicare and Medicare Services) to issue a statement regarding mandating electronic strip count.  While there are many other drivers that can generate substantial revenue after the upcoming commercial launch of HeC this year, that is clearly the “big daddy” as CMS provides coverage for more than 10 million persons with diabetes each year.  ALR’s technology outstrips its limited number of competitors that have FDA clearance in either price or function, leaving it in a very enviable spot should the federal agency take regulatory actions in an attempt to curtail waste associated with diabetes care.

The PDF of the Taglich Report as well as much more pertinent investor information is available on the ALRT website.

The Taglich Brothers’ report on ALR Technologies, Inc.  in PowerPoint format:

ALR Technologies (ALRT) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated three thousand dollars for one month of consultation and journalism services and to manage an investor relations/awareness program by ALR Technologies. Viper has completed prior service agreements with ALRT Technologies with full disclosure listed on our disclaimer/disclosure page. Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Cardium to Present at Rodman and Renshaw Conference

Cardium to Present at Rodman and Renshaw Conference(0)

Cardium to Present at the Rodman & Renshaw Annual 2012 Healthcare Investment Conference Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Chairman & CEO will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012 at 3:15 p.m. Eastern Time. The conference is being held September 9-11,

Stocks Mixed as Housing Data Helps and Consumer Confidence Hinders

Stocks Mixed as Housing Data Helps and Consumer Confidence Hinders(0)

U.S. stocks were mired in a tight range Tuesday, getting some support from a better-than-expected report on the U.S. housing market. The Dow Jones industrial average demurred 21.68 points to 13,102.99. The S&P 500 index gave back 1.14 points to 1,409.30, but the tech-heavy Nasdaq Composite Index was positive by 3.95 points to 3,077.14. The

ALR Technologies Nears Commercialization of Diabetes Management Systems

ALR Technologies Nears Commercialization of Diabetes Management Systems(0)

Following an announcement earlier this month providing shareholders with an update on the commercial launch of its Health-e-Connect system for remote monitoring and chronic disease management, ALR Technologies released news today further detailing its systems, including a unique universal cable.  As part of the introduction of the universal cable, ALR provided pictures on their website. 

Apple Asks Courts to Ban Some Samsung Smartphone Sales

Apple Asks Courts to Ban Some Samsung Smartphone Sales(0)

After winning its patent infringement case against Samsung last Friday, Apple (NASDAQ: AAPL) has now come right back to the courts asking for a preliminary injunction against eight Samsung smartphones that it wants pulled from shelves and banned from sales.  The case, which was decided by a California jury verdict on August 24 after a

Bristol Abandons Trials for Promising Hepatitis C Drug

Bristol Abandons Trials for Promising Hepatitis C Drug(0)

In the biotechnology world, the sun rises and set around the two key words “safety” and “efficacy.”  A serious safety concern resulted in Bristol-Myers Squibb (NYSE: BMY) voluntarily halting its ongoing Phase 2 study of BMS-986094, a drug in development as a new indication for hepatitis C as part of the drug maker’s quest for

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.